Waverley Pharma, Inc. is a pharmaceutical company, which engages in the commercialization and development of oncology drugs. Its products include Pemetrexed, WAV-102, and PARP-1 Inhibitors. The company was founded in 2014 and is headquartered in Winnipeg, Canada.